Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1315-1322

  Ju, Jing Fang ^a   Banerjee, Debabrata ^b   Lenz, Heinz Josef ^a   Danenberg, Kathleen D ^a   Schmittgen, Thomas C ^a   Spears, C Paul ^a   Schönthal, Axel H ^a   Manno, David J ^a   Hochhauser, Daniel ^b   Bertino, Joseph R ^b   Danenberg, Peter V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DNA; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; MITOMYCIN C; PROTEIN P53; RALTITREXED;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL STRAIN HL 60; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORODEOXYURIDYLATE; GENES, BCL-2; GENES, P53; HL-60 CELLS; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION;

EID: 15144352586     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 88: 1442-1455, 1996.
2. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
3. Takahashi, T., Carbone, D., Takahashi, T., Nau, M. M., Hida, T., Linnoila, I., Ueda, R., and Minna, D. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res., 52: 2340-2343, 1992.
4. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
5. Liu, T-J., Zhang, W-W., Taylor, D. L., Roth, J. A., Goepfert, T. H., and Clayman, G. L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res., 54: 3662-3667, 1994.
6. Lee, J. M., and Bernstein, A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev., 14: 149-161, 1995.
7. Fujiwara, T., Cai, D. W., Georges, R. N., Mukhopadhyay, T., Grimm, E. A., and Roth, J. A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst., 86: 1458-1462, 1994.
8. Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M-T., Huang, W-M., Johnson, D. E., Anderson, S. C., Wen, S. F., Bookstein, R., Shepard, H. M., and Gregory, R. J. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy. Hum. Gene Ther., 5: 1079-1088, 1994.
9. Lesson-Wood, L. A., Kim, W. H., Kleinman, H. K., Weintraub, B. D., and Mixson, A. J. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum. Gene Ther., 6: 395-405, 1995.
10. Hamada, K., Alemany, R., Zhang, W. W., Hittleman, W. N., Lotan, R., Roth, J. A., and Mitchell, M. F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res., 56: 3047-3054, 1996.
11. Clayman, G. L., Liu, T. J., Overholt, S. M., Mobley, S. R., Wang, M., Janot, F., and Goepfert, H. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/ CIP1 (p21). Arch. Otolaryngol. Head Neck Surg., 122: 489-493, 1996.
12. Bookstein, R., Demers, W., Gregory, R., Maneval, D., Park, J., and Wills, K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin. Oncol., 23: 66-77, 1996.
13. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
14. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
15. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
16. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 72: 539-542, 1994.
17. Kinzler, K. W., and Vogelstein, B. Clinical implications of basic research: cancer therapy meets p53. N. Engl. J. Med., 331: 49-50, 1994.
18. Fujiwara, T., Grimm, E., Mukhopadhyay, T., Zhang, W-W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
19. Yang, B., Eshleman, J. R., Berger, N. A., and Markowitz, S. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res., 2: 1649-1657, 1996.
20. Banerjee, D., Lenz, H-J., Schnieders, B., Manno, D. J., Ju, J-F., Spears, C. P., Hochhauser, D., Danenberg, K., Danenberg, P., and Bertino, J. R. Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL-60 cells and increases their sensitivity to stress. Cell Growth Differ., 6: 1405-1413, 1995.
21. Vistica, D. T., Skehan, P., Scudiero, D., Monks, A., Pittman, A., and Boyd, M. R. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan formation. Cancer Res., 51: 2515-2520, 1991.
22. Gavrielli, Y., Shermna, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labelling of endonuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
23. Johnston, P. G., Lenz, H-J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
24. Horikoshi, T., Danenberg, K. D., Stadibauer, T. H. W., Volkenandt, M., Shea, L. L. C., Aigner, K., Gustavsson, B., Leichman, L., Prösing, R., Ray, M., Gibson, N. W., Spears, C. P., and Danenberg, P. V. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res., 52: 108-116, 1992.
25. Heidelberger, C., Danenberg, P. V., and Moran, R. G. Fluorinated pyrimidines and their nucleosides. Adv. Enzymol. Relat. Areas Mol. Biol., 54: 58-119, 1983.
26. Dusenberry, C. E., Davis, M. A., Lawrence, T. S., and Maybaum, J. Induction of megabase DNA fragments by 5-fluorodeoxyuridine in human colorectal tumor (HT-29) cells. Mol. Pharmacol., 39: 285-289, 1990.
27. Fan, S., El-deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia. K., Fornace, A. J., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
28. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
29. Yang, E., and Korsmeyer, S. Molecular thanaptosis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
30. Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J. J., May, P., and Oren, M. p53-mediated cell death: relationship to cell cycle control. Mol. Cell Biol., 13: 1415-1423, 1993.
31. Harper, J. W., Adami, G. R., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
32. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
33. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potent mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
34. Chen, X., Bargonetti, S., and Prives, C. p53, through p21 (WAF1/ CIP1), induces cyclin D1 synthesis. Cancer Res., 55: 4257-4263, 1995.
35. Wolf, D., and Rotter, V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. USA, 82: 790-799, 1985.
36. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell Biol., 14: 1815-1823, 1994.
37. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Lieberman, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
38. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299, 1995.
39. Zhan, Q., Fan, S., Bae, I., Guilloff, C., Lieberman, D. A., O'Connor, P. M., and Fornace, A. J. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9: 3743-3751, 1994.
40. Kastan, M. B. Signalling to p53: where does it all start? BioEssays, 18: 617-619, 1996.
41. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
42. Delmastro, D. A., Li, J., Vaisman, A., Solle, M., and Chaney, S. G. DNA damage inducible-gene expression following platinum treatment in ovarian carcinoma cell lines. Cancer Chemother. Pharmacol., 39: 245-253, 1997.
43. Smith, M. L., Kontny, H. U., Zhan, Q., Sreenath, A., O'Connor, P. M., and Fornace, A. J., Jr. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to U.V. radiation or cisplatin. Oncogene, 13: 2255-2263, 1996.
44. Cleaver, J. Thymidine Metabolism and Cell Kinetics. Amsterdam: North Holland Publishing Co., 1967.
45. Kufe, D. W., Egan, E. M., Rosowsky, A., Ensminger, W., and Frei, E., III. Thymidine arrest and synchrony of cellular growth in vivo. Cancer Treat. Rep., 64: 1307-1321, 1980.
46. Linke, S. P., Clarkin, K. C., Dileonardo, A., Tsou, A., and Wahl, G. M. A reversible, p53-dependent cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev., 10: 934-947, 1996.
47. Bjursell, G., and Reichard, P. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells. J. Biol. Chem., 248: 3904-3909, 1973.
48. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-333, 1995.
49. Sewing, A., and Muller, R. Protein kinase A phosphorylates cyclin D1 at three distinct sites within the cyclin box and at the C-terminus. Oncogene, 9: 2733-2736, 1994.